Education
About Us
Working with TipRanks
Follow Us
Titan Pharmaceuticals (TTNP)
NASDAQ:TTNP
TTNP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.03 - $5.76
Previous CloseN/A
Volume3.24K
Average Volume (3M)64.33K
Market Cap
$5.67M
Enterprise ValueN/A
Total Cash (Recent Filing)$2.80M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.12
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.23
Shares Outstanding1,330,234
10 Day Avg. Volume13,635
30 Day Avg. Volume64,326
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Titan Pharmaceuticals News
TTNP FAQ
What was Titan Pharmaceuticals’s price range in the past 12 months?
Titan Pharmaceuticals lowest stock price was $3.03 and its highest was $5.76 in the past 12 months.
What is Titan Pharmaceuticals’s market cap?
Titan Pharmaceuticals’s market cap is $5.67M.
When is Titan Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Titan Pharmaceuticals’s earnings last quarter?
Titan Pharmaceuticals released its earnings results on Nov 13, 2023. The company reported -$0.022 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.022.
Is Titan Pharmaceuticals overvalued?
According to Wall Street analysts Titan Pharmaceuticals’s price is currently Overvalued.
Does Titan Pharmaceuticals pay dividends?
Titan Pharmaceuticals does not currently pay dividends.
What is Titan Pharmaceuticals’s EPS estimate?
Titan Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Titan Pharmaceuticals have?
Titan Pharmaceuticals has 1,330,234 shares outstanding.
What happened to Titan Pharmaceuticals’s price movement after its last earnings report?
Titan Pharmaceuticals reported an EPS of -$0.022 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.556%.
Which hedge fund is a major shareholder of Titan Pharmaceuticals?
Currently, no hedge funds are holding shares in TTNP
Company Description
Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. (TTNP) is a biopharmaceutical company focused on developing and commercializing innovative treatments for serious medical conditions. With a strong emphasis on the central nervous system and opioid addiction treatment markets, Titan's core product is Probuphine, a unique subdermal implant designed to deliver a continuous and controlled dose of buprenorphine for opioid dependence management.
Technical Analysis
NovaBay Pharma
―
Hepion Pharmaceuticals
―
Quoin Pharmaceuticals
―
InMed Pharmaceuticals
―
Galecto
―
Ownership Overview
― Insiders
0.83% Mutual Funds
0.80% Other Institutional Investors
98.16% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---